释放潜力:针对瘤微环境中的代谢途径进行癌症治疗
Siyuan Jia1, Ann M Bode2, Xue Chen3
1Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, PR China; Key Laboratory of Carcinogenesis and Invasion, Chinese Ministry of Education, Cancer Research Institute, School of Basic Medicine, Central South University, Changsha, Hunan 410078, PR China.
癌细胞重新编程瘤微环境 (TME) 代谢,推动瘤生长和抵抗. 向癌症相关纤维细胞 (CAF),巨细胞 (TAM),淋巴细胞 (TIL) 和内皮细胞 (TEC) 的代谢途径提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 代谢途径 代谢途径
背景情况:
- 全球癌症发病率和死亡率正在上升.
- 瘤微环境 (TME) 内的代谢重编程对于癌症的发展,进展,转移和耐药性至关重要.
- 瘤细胞积极改变TME中周围细胞的新陈代谢.
研究的目的:
- 检查TME内的关键细胞子集的代谢重编程:与癌症相关的纤维细胞 (CAF),与瘤相关的巨细胞 (TAM),瘤透淋巴细胞 (TIL) 和瘤内皮细胞 (TEC).
- 了解这些细胞与瘤细胞之间有关代谢重编程的相互作用.
- 审查针对这些代谢途径的当前和新兴疗法,特别是与免疫检查点阻塞疗法结合使用.
主要方法:
- 专注于TME中四个主要细胞子集的代谢重编程:CAF,TAM,TIL和TEC.
- 通过细胞因子和代谢产物对代谢基质竞争和代谢诱导的分析.
- 在TME中针对细胞代谢的治疗策略的审查.
主要成果:
- 瘤细胞诱导CAF,TAM,TIL和TEC的代谢变化.
- 这种代谢重编程支持瘤细胞生长,促进免疫抑制,并促进血管生成.
- 瘤细胞和TME组件之间的相互作用涉及复杂的代谢交叉对话.
结论:
- 在TME中代谢重编程是癌症的一个关键标志.
- 针对CAFs,TAMs,TILs和TECs的代谢途径提供了有希望的治疗途径.
- 组合疗法,包括针对新陈代谢和免疫检查点的组合疗法,可以提高治疗效率.
更多相关视频
06:21Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
09:42Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis
Published on: June 26, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Tumor Microenvironment
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
